EffRx

EffRx, Inc. is a drug delivery company that utilizes value-added drug delivery technologies to improve the performance of established pharmaceuticals. The Company applies its technologies to well established, proven compounds to develop reformulated products with reduced gastrointestinal side effects, better absorption, and faster onset of action. EffRx develops novel prescription and OTC pharmaceuticals at relatively low development cost and risk, shorter time to market and with premium pricing compared with generics.

www.effrx.com

Based in Waltham Massachusetts, EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate® II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. We believe the EyeGate® II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.

http://www.eyegatepharma.com

U3 Pharma AG is an emerging leader in targeted cancer drug development. The company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Prof. Axel Ullrich

http://www.u3pharma.com

 Status: Successfully divested in 2008

Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions.
Hybrigenics’ most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with current reference treatments, for improved efficacy and better tolerance.
Hybrigenics’ research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types.
Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service activities.
Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate, financial and administrative management. The core link among all Hybrigenics activities is trust in science for life. Hybrigenics went public in December 2007.

http://www.hybrigenics.com/

WILEX is a biopharmaceutical company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich.

WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body.

Wilex had its initial public offering in late 2006.

http://www.wilex.com

 Status: successfully divested

CLL Pharma

In 1995, when CLL PHARMA was founded on the French Riviera, we set ourselves the dual target of providing movers in the pharmaceutical world, and patients, with access to:
 
- drugs providing very high levels of quality, safety and efficacy together with a more favourable price structure
- innovative galenical formulations able to producing better treatment acceptance and compliance.

Today, with 50 marketing authorizations, over 30 development projects and 80 international patents involving 5 drug delivery technologies, we can only feel proud of the progress made and confident of what we may yet do.

By the end of 2005, CLL PHARMA purchased SYN:TEM, a Drug Discovery company specialised in peptides chemistry, and owner of a technology named PEPTRANS, allowing to vectorise and facilitate Blood Brain Barrier passage for molecules aiming for central nervous system.

Five new molecules are proposed in two different therapeutic axes : pain and cancer.

www.cllpharma.com

(divested 2004)